Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 4/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25659799 | 0.88 | NR1H2 (0.39) | HPGDKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL9938408 | 0.87 | HPGD (0.48) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL14698843 | 0.85 | HPGD (0.46) | HPGDRECQLGAAPTPN2PTPN1 | |
| SCHEMBL15647563 | 0.84 | MAPT (0.46) | GAAKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL15645751 | 0.84 | MAPT (0.46) | GAAKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL28779606 | 0.84 | HPGD (0.55) | HPGDRECQLGAAPTPN2PTPN1 | |
| SCHEMBL1014327 | 0.81 | CYP2C9 (0.46) | RECQLGAAKMT2AALDH1A1MEN1 | |
| SCHEMBL1014326 | 0.81 | CYP2C9 (0.46) | RECQLGAAKMT2AALDH1A1MEN1 | |
| SCHEMBL31587550 | 0.81 | CYP2C9 (0.46) | RECQLGAAKMT2AALDH1A1MEN1 | |
| SCHEMBL28228568 | 0.78 | CYP2C9 (0.44) | GAAKMT2AALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035790-B2 | RORγ modulators | RORB, RORA, RORC | HPGD 1147/4885RECQL 665/4885GAA 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.